Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesions

Cancer

Volumn 115, Issue 7, 2009, Pages 1498-1506

  Pu, Xia ^a   Lippman, Scott M ^a   Yang, Hushan ^a   Lee, J Jack ^a   Wu, Xifeng ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cox 2, polymorphism; Diplotype; Haplotype; Oral premalignant lesion

Indexed keywords

CYCLOOXYGENASE 2;

ADULT; ALLELE; ARTICLE; CANCER GROWTH; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA POLYMORPHISM; EXON; FEMALE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HISTOPATHOLOGY; HUMAN; LEUKOPLAKIA; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ADULT; ALCOHOL DRINKING; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; POLYMORPHISM, GENETIC; PRECANCEROUS CONDITIONS; RISK FACTORS; SMOKING;

EID: 63449084313     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24157     Document Type: Article

References (34)

1. Pandey M, Prakash O, Santhi WS, Soumithran CS, Pillai RM. Overexpression of COX-2 gene in oral cancer is independent of stage of disease and degree of differentiation. Int J Oral Maxillofac Surg. 2008;37:379-383.
2. Kademani D. Oral cancer. Mayo Clin Proc. 2007;82:878-887.
3. Mithani SK, Mydlarz WK, Grumbine FL, Smith IM, Cali- fano JA. Molecular genetics of premalignant oral lesions. Oral Dis. 2007;13:126-133.
4. Silverman S Jr, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer. 1984;53:563-568.
5. Hashibe M, Sankaranarayanan R, Thomas G, et al. Alcohol drinking, body mass index and the risk of oral leukoplakia in an Indian population. Int JCancer. 2000;88:129-134.
6. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin. 2002;52:195-215.
7. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
8. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7:211-217.
9. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72:1605-1621.
10. Wang Z. The role of COX-2 in oral cancer development, and chemoprevention/treatment of oral cancer by selective COX-2 inhibitors. Curr Pharm Des. 2005;11:1771-1777.
11. Banerjee AG, Gopalakrishnan VK, Bhattacharya I, Vishwa- natha JK. Deregulated cyclooxygenase-2 expression in oral premalignant tissues. Mol Cancer Ther. 2002;1:1265-1271.
12. Kwak YE, Jeon NK, Kim J, Lee EJ. The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma. Ann N Y Acad Sci. 2007;1095:99-112.
13. Sumitani K, Kamijo R, Toyoshima T, et al. Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production. J Oral Pathol Med. 2001;30:41-47.
14. Minter HA, Eveson JW, Huntley S, Elder DJ, Hague A. The cyclooxygenase 2-selective inhibitor NS398 inhibits pro-liferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. Clin Cancer Res. 2003;9:1885-1897.
15. Chung FM, Yang YH, Chen CH, Lin CC, Shieh TY. An-
16. giotensin-converting enzyme gene insertion/deletion polymorphism is associated with risk of oral precancerous lesion in betel quid chewers. Br J Cancer. 2005;93:602-606.
17. Kao SY, Wu CH, Lin SC, et al. Genetic polymorphism of cytochrome P4501A1 and susceptibility to oral squamous cell carcinoma and oral precancer lesions associated with smoking/betel use. J Oral Pathol Med. 2002;31:505-511.
18. Wang Y, Spitz MR, Lee JJ, Huang M, Lippman SM, Wu X. Nucleotide excision repair pathway genes and oral pre- malignant lesions. Clin Cancer Res. 2007;13:3753-3758.
19. Huang M, Spitz MR, Gu J, et al. Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions. Carcinogenesis. 2006;27:2034-2037.
20. Schwartzbaum JA, Ahlbom A, Lonn S, et al. An international case-control study of interleukin-4Ralpha, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk. Cancer Epidemiol Biomarkers Prev. 2007;16:2448-2454.
21. Lin YC, Huang HI, Wang LH, et al. Polymorphisms of COX-2 -765G→C and p53 codon 72 and risks of oral squamous cell carcinoma in a Taiwan population. Oral Oncol. 2008;44:798-804.
22. Tan W, Wu J, Zhang X, et al. Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxy- genase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis. 2007;28:1197-1201.
23. Yang H, Gu J, Lin X, et al. Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. Clin Cancer Res. 2008;14:2236-2244.
24. Hudmon KS, Honn SE, Jiang H, et al. Identifying and recruiting healthy control subjects from a managed care organization: a methodology for molecular epidemiological case-control studies of cancer. Cancer Epidemiol Biomarkers Prev. 1997;6:565-571.
25. Pannone G, Bufo P, Caiaffa MF, et al. Cyclooxygenase-2 expression in oral squamous cell carcinoma. Int J Immuno-pathol Pharmacol. 2004;17:273-282.
26. Langsenlehner U, Yazdani-Biuki B, Eder T, et al. The cy- clooxygenase-2 (PTGS2) 8473T!C polymorphism is associated with breast cancer risk. Clin Cancer Res. 2006;12:1392-1394.
27. Hu Z, Miao X, Ma H, et al. A common polymorphism in the 3'UTR of cyclooxygenase 2/prostaglandin synthase 2 gene and risk of lung cancer in a Chinese population. Lung Cancer. 2005;48:11-17.
28. Park JM, Choi JE, Chae MH, et al. Relationship between cyclooxygenase 8473T!C polymorphism and the risk of lung cancer: a case-control study [serial online]. BMC Cancer. 2006;6:70.
29. Papafili A, Hill MR, Brull DJ, et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arte- rioscler Thromb Vasc Biol. 2002;22:1631-1636.
30. Lira MG, Mazzola S, Tessari G, et al. Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation. Br J Dermatol. 2007;157:49-57.
31. Sitarz R, Leguit RJ, de Leng WW, et al. The COX-2 promoter polymorphism -765 G→C is associated with early- onset, conventional and stump gastric cancers. Mod Pathol. 2008;21:685-690.
32. Ulrich CM, Whitton J, Yu JH, et al. PTGS2 (COX-2) -765G→C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev. 2005;14:616-619.
33. Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, Canzian F. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis. 2004;25:229-235.
34. Moons LM, Kuipers EJ, Rygiel AM, et al. COX-2 CA-hap-lotype is a risk factor for the development of esophageal ad- enocarcinoma. Am JGastroenterol. 2007;102:2373-2379.